Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.
2.

Metallographic in situ hybridization.

Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, Tubbs RR.

Hum Pathol. 2007 Aug;38(8):1145-59. Review.

PMID:
17640553
3.

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

PMID:
17536315
4.
5.

Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.

Tubbs RR, Pettay JD, Swain E, Roche PC, Powell W, Hicks DG, Grogan T.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):436-40.

PMID:
17122642
6.

Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.

Fitzgibbons PL, Murphy DA, Dorfman DM, Roche PC, Tubbs RR; Immunohistochemistry Committee, College of American Pathologists.

Arch Pathol Lab Med. 2006 Oct;130(10):1440-5.

PMID:
17090184
7.

The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study.

Dorfman DM, Bui MM, Tubbs RR, Hsi ED, Fitzgibbons PL, Linden MD, Rickert RR, Roche PC; College of American Pathologists Cell Markers Committee.

Arch Pathol Lab Med. 2006 Jun;130(6):779-82.

PMID:
16740027
8.

Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.

Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL.

Clin Cancer Res. 2005 May 15;11(10):3722-32.

9.

Endometrial cancer: can nodal status be predicted with curettage?

Mariani A, Sebo TJ, Katzmann JA, Roche PC, Keeney GL, Lesnick TG, Podratz KC.

Gynecol Oncol. 2005 Mar;96(3):594-600.

PMID:
15721399
10.

Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue.

Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, Roche PC, Spelsberg TC.

Breast Cancer Res Treat. 2004 Jul;86(1):75-88.

PMID:
15218362
11.

Molecular and histopathologic predictors of distant failure in endometrial cancer.

Mariani A, Sebo TJ, Webb MJ, Riehle D, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC.

Cancer Detect Prev. 2003;27(6):434-41.

PMID:
14642551
12.

Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma.

Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, Murphy LM, Chen L, Wettstein PJ, Gostout B, Ferrone S, Strome SE.

Cancer. 2003 May 1;97(9):2203-11.

13.

Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.

Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, Hartmann LC, Hellström I, Strome SE.

Gynecol Oncol. 2003 Apr;89(1):99-104.

PMID:
12694661
14.

Detection of mammaglobin in the sera of patients with breast cancer.

Fanger GR, Houghton RL, Retter MW, Hendrickson RC, Babcook J, Dillon DC, Durham MD, Reynolds LD, Johnson JC, Carter D, Fleming TP, Roche PC, Persing DH, Reed SG.

Tumour Biol. 2002 Jul-Aug;23(4):212-21.

PMID:
12499777
15.

Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.

Reinholz MM, Iturria SJ, Ingle JN, Roche PC.

Breast Cancer Res Treat. 2002 Jun;74(3):255-69.

PMID:
12206515
16.

Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.

Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA.

Endocrinology. 2002 Sep;143(9):3259-67.

PMID:
12193537
17.

Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors.

Lae ME, Roche PC, Jin L, Lloyd RV, Nascimento AG.

Am J Surg Pathol. 2002 Jul;26(7):823-35.

PMID:
12131150
18.

Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.

Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W.

Oncogene. 2002 Jul 18;21(31):4863-71.

19.

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L.

Nat Med. 2002 Aug;8(8):793-800. Epub 2002 Jun 24. Erratum in: Nat Med 2002 Sep;8(9):1039.

PMID:
12091876
20.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA.

J Natl Cancer Inst. 2002 Jun 5;94(11):855-7.

PMID:
12048274
21.

Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients.

Adem C, Reynolds C, Adlakha H, Roche PC, Nascimento AG.

Histopathology. 2002 Jun;40(6):556-62.

PMID:
12047767
22.

Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.

Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD.

Clin Cancer Res. 2002 May;8(5):1085-91.

23.

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE.

Mayo Clin Proc. 2002 Feb;77(2):148-54.

PMID:
11838648
24.

Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts.

Thompson DL, Sabbagh Y, Tenenhouse HS, Roche PC, Drezner MK, Salisbury JL, Grande JP, Poeschla EM, Kumar R.

J Bone Miner Res. 2002 Feb;17(2):311-20.

25.

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.

Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ.

J Biol Chem. 2001 Oct 19;276(42):38830-6. Epub 2001 Aug 8.

26.

hMLH1 and hMSH2 expression in human hepatocellular carcinoma.

Wang L, Bani-Hani A, Montoya DP, Roche PC, Thibodeau SN, Burgart LJ, Roberts LR.

Int J Oncol. 2001 Sep;19(3):567-70.

PMID:
11494037
27.

Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells.

Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J, Jiang J, Schmidt C, Frudakis A, Repasky E, Maltez Filho A, Nolasco M, Badaro R, Zhang X, Roche PC, Persing DH, Reed SG.

Mol Diagn. 2001 Jun;6(2):79-91.

PMID:
11468693
28.

Expression of an immediate early gene, IEX-1, in human tissues.

Feldmann KA, Pittelkow MR, Roche PC, Kumar R, Grande JP.

Histochem Cell Biol. 2001 Jun;115(6):489-97.

PMID:
11455449
29.
30.

Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization.

Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, Roche PC, Lloyd RV.

Am J Surg Pathol. 2001 Jul;25(7):911-7.

PMID:
11420462
31.

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.

Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM.

J Clin Oncol. 2001 May 15;19(10):2714-21.

PMID:
11352964
32.

Immunohistochemical Analysis for hMLH1 and hMSH2 Expression in Colorectal Cancer.

Halling KC, Roche PC.

Methods Mol Med. 2001;50:81-6. doi: 10.1385/1-59259-084-5:81.

PMID:
21318818
34.

17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.

Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ.

Cancer Res. 2000 Oct 1;60(19):5371-5.

35.

Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling.

Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN.

Nat Genet. 2000 Oct;26(2):146-7. No abstract available. Erratum in: Nat Genet 2000 Dec;26(4):501.

PMID:
11017067
36.

Prognostic value of bone marrow angiogenesis in multiple myeloma.

Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR.

Clin Cancer Res. 2000 Aug;6(8):3111-6.

37.

Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development.

Rogers MS, Foley MA, Crotty TB, Hartmann LC, Ingle JN, Roche PC, Strehler EE.

Neoplasia. 1999 Aug;1(3):220-5.

38.

Pretreatment assessment of prognostic indicators in endometrial cancer.

Mariani A, Sebo TJ, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC.

Am J Obstet Gynecol. 2000 Jun;182(6):1535-44.

PMID:
10871476
39.

HMSH6 alterations in patients with microsatellite instability-low colorectal cancer.

Parc YR, Halling KC, Wang L, Christensen ER, Cunningham JM, French AJ, Burgart LJ, Price-Troska TL, Roche PC, Thibodeau SN.

Cancer Res. 2000 Apr 15;60(8):2225-31.

40.

Adenoma-specific alterations of protein kinase C isozyme expression in Apc(MIN) mice.

Klein IK, Ritland SR, Burgart LJ, Ziesmer SC, Roche PC, Gendler SJ, Karnes WE Jr.

Cancer Res. 2000 Apr 15;60(8):2077-80.

41.

Assessment of inhibin and p53 in granulosa cell tumors of the ovary.

Gebhart JB, Roche PC, Keeney GL, Lesnick TG, Podratz KC.

Gynecol Oncol. 2000 May;77(2):232-6.

PMID:
10785470
42.

Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool.

Limburg PJ, Ahlquist DA, Gilbert JA, Harrington JJ, Klee GG, Roche PC.

Dig Dis Sci. 2000 Mar;45(3):494-9.

PMID:
10749323
43.

Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.

Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC.

Gynecol Oncol. 2000 Apr;77(1):1-7.

PMID:
10739683
44.
45.

p73 mutations are not detected in sporadic and hereditary breast cancer.

Schwartz DI, Lindor NM, Walsh-Vockley C, Roche PC, Mai M, Smith DI, Liu W, Couch FJ.

Breast Cancer Res Treat. 1999 Nov;58(1):25-9.

PMID:
10634515
46.

Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer.

Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC.

J Endocrinol. 1999 Dec;163(3):495-504.

PMID:
10588823
47.

MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors.

Cheville JC, Roche PC.

Mod Pathol. 1999 Oct;12(10):974-8.

PMID:
10530563
48.

Increased HER2 with U.S. Food and Drug Administration-approved antibody.

Roche PC, Ingle JN.

J Clin Oncol. 1999 Jan;17(1):434. No abstract available.

PMID:
10458264
49.

Extension of useful reagent shelf life beyond manufacturers' recommendations. Cell Markers Committee of the College of American Pathologists.

Tubbs RR, Nagle R, Leslie K, Pettigrew NM, Said JW, Corwin DJ, Rickert RR, Roche PC.

Arch Pathol Lab Med. 1998 Dec;122(12):1051-2.

PMID:
9870851
50.

Molecular markers in male breast carcinoma.

Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH.

Cancer. 1998 Nov 1;83(9):1947-55.

PMID:
9806653

Supplemental Content

Loading ...
Support Center